Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2016 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biotechnology company focused on creating and developing novel protease therapeutics to treat serious medical conditions in the field of hemostasis, today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference, being held in New York City September 12-13, 2016.
Rodman & Renshaw 18th Annual Global Investment Conference – Catalyst Biosciences Presentation Details
| Date: | Tuesday, September 13, 2016 | |||
| Time: | 9:10 a.m. Eastern Time | |||
| Location: | The Lotte New York Palace Hotel, Kennedy II Room |
About Catalyst Biosciences, Inc.
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address serious medical conditions. Catalyst is focused on the field of hemostasis, including the treatment of hemophilia and surgical bleeding. Catalyst’s most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d (marzeptacog alfa), which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. Catalyst has a next-generation Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development. For more information, please visit www.catalystbiosciences.com
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the Company’s product candidates, including product development plans for CB 2679d and CB 813d, plans for and timing of clinical trials, and the potential uses of the Company’s product candidates are forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, potential adverse effects arising from the testing or use of the Company’s products, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, risks related to the Company’s ability to protect or enforce intellectual property rights related to its product candidates, competition and other factors that affect the Company’s ability to establish collaborations on commercially reasonable terms and the Company’s ability to successfully develop and commercialize its product candidates. Other risks and uncertainties related to the Company’s business are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
CONTACTS: Investors: Andrew McDonald Managing Director LifeSci Advisors, LLC +1.646.597.6987 [email protected] Fletcher Payne, CFO Catalyst Biosciences, Inc. +1.650.871.0761 [email protected] Media: Denise Powell Red House Consulting, LLC +1.510.703.9491 [email protected]
